Literature DB >> 33358667

Right Heart Strain on Presenting 12-Lead Electrocardiogram Predicts Critical Illness in COVID-19.

Mohamad Raad1, Sarah Gorgis1, Mohammed Dabbagh1, Omar Chehab2, Sachin Parikh1, Gurjit Singh3.   

Abstract

OBJECTIVES: This study aimed to assess the association of new right heart strain patterns on presenting 12-lead electrocardiogram (RHS-ECG) with outcomes in patients hospitalized with COVID-19.
BACKGROUND: Cardiovascular comorbidities and complications, including right ventricular dysfunction, are common and are associated with worse outcomes in patients with COVID-19. The data on the clinical usefulness of the 12-lead ECG to aid with prognosis are limited.
METHODS: This study retrospectively evaluated records from 480 patients who were consecutively admitted with COVID-19. ECGs obtained at presentation in the emergency department (ED) were considered index ECGs. RHS-ECG was defined by any new right-axis deviation, S1Q3T3 pattern, or ST depressions with T-wave inversions in leads V1 to V3 or leads II, III, and aVF. Multivariable logistic regression was performed to assess whether RHS-ECGs were independently associated with primary outcomes.
RESULTS: ECGs from the ED were available for 314 patients who were included in the analysis. Most patients were in sinus rhythm, with sinus tachycardia being the most frequent dysrhythmia. RHS-ECG findings were present in 40 (11%) patients. RHS-ECGs were significantly associated with the incidence of adverse outcomes and an independent predictor of mortality (adjusted odds ratio [adjOR]: 15.2; 95% confidence interval [CI]: 5.1 to 45.2; p < 0.001), the need for mechanical ventilation (adjOR: 8.8; 95% CI: 3.4 to 23.2; p < 0.001), and their composite (adjOR: 12.1; 95% CI: 4.3 to 33.9]; p < 0.001).
CONCLUSIONS: RHS-ECG was associated with mechanical ventilation and mortality in patients admitted with COVID-19. Special attention should be taken in patients admitted with new signs of RHS on presenting ECG.
Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  COVID-19; ECG; emergency department; right heart strain; right ventricular dysfunction

Year:  2020        PMID: 33358667      PMCID: PMC7500909          DOI: 10.1016/j.jacep.2020.09.013

Source DB:  PubMed          Journal:  JACC Clin Electrophysiol        ISSN: 2405-500X


Coronavirus disease-2019 (COVID-19) is caused by the novel severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). It was first discovered in late 2019 in Wuhan, China, and has since caused a global pandemic affecting >25 million people worldwide and 6 million in the United States (1). Several risk factors have been reported to be associated with COVID-19 severity and outcomes. Emerging information has revealed that cardiovascular complications, including right ventricular (RV) dysfunction and cor pulmonale, are common and confer worse outcomes in patients admitted with COVID-19 (2,3). Clinical tools such as troponin levels, 12-lead electrocardiograms (ECGs), and echocardiograms are being used to aid with diagnosis and prognosis, although there is limited information due to lack of data. This study aimed to describe the characteristics and outcomes of patients admitted with COVID-19 in a tertiary referral center emergency department (ED) and to assess whether new right heart strain patterns on presenting ECGs (RHS-ECGs) were associated with specific outcomes.

Methods

Cohort patient population

We retrospectively evaluated the records of 480 patients consecutively admitted with COVID-19 at a tertiary care center in the metropolitan Detroit area between March 9 and April 1, 2020. Patients were included if they were diagnosed with COVID-19 and had a baseline ECG recorded in the ED. COVID-19 was diagnosed using molecular diagnostic testing of the nasopharynx or bronchial secretions using reverse transcription polymerase chain reaction to identify SARS-CoV-2 RNA. Our method was validated against the Centers for Disease Control and Prevention reference method to meet or exceed the level of detection required under the Food and Drug Administration Emergency Use Authorization guidelines.

Definition of variables and outcomes

Demographics, vital signs, comorbid conditions, laboratory, and radiological data at hospital admission were manually collected from the electronic health records (Table 1 , Supplemental Table 1). Symptoms were deemed positive if endorsed within 24 h of presentation. Baseline results referred to initial blood samples collected in the ED or the first values within 24 h of admission. Comorbid conditions were identified based on admission diagnoses.
Table 1

Clinical Characteristics of Patients According to the Presence or Absence of Signs of RHS on the Presenting 12-Lead ECG

Overall (N = 314)RHS-ECG
p Value
With (n = 34)Without (n = 280)
Demographic characteristic
 Age, yrs60 ± 1565 ± 1559 ± 150.021
 Number of patients ≥65 yrs117 (37)20 (59)97 (35)0.006
 Sex
 Women151 (48)19 (56)132 (47)0.335
 Men163 (52)15 (44)148 (53)
 Body mass index, kg/m233 (29−41)34 (30−41)33 (29−42)0.164
 Vital signs and oxygenation on admission
  Mean arterial pressure, mm Hg80 (72−88)80 (71−91)80 (72−88)0.525
  SPO2:FiO2 ratio359 (301−452)333 (239−405)359 (311−452)0.053
 Symptoms on admission
  Chest pain64 (20)11 (32)53 (19)0.067
  Shortness of breath220 (70)28 (82)192 (69)0.098
  Cough234 (75)25 (74)209 (75)0.888
Comorbid conditions
 Hypertension232 (74)25 (74)207 (74)0.960
 Diabetes mellitus151(48)21 (62)130 (46)0.091
 Coronary artery disease47 (15)8 (24)39 (14)0.138
 Cerebrovascular disease13 (4)4 (12)9 (3)0.019
 Atrial fibrillation/flutter13 (4)3 (9)10 (4)0.147
 Chronic kidney disease122 (39)17 (50)105 (38)0.158
 Chronic obstructive pulmonary disease36 (12)10 (29)26 (9)0.001
 Asthma45 (14)3 (9)42 (15)0.332
 Obstructive sleep apnea31 (10)3 (9)28 (10)0.828
 Chronic hypoxic respiratory failure9 (3)2 (6)7 (3)0.264
 Smoking history112 (36)18 (53)94 (34)0.026
 Immunosuppression21 (7)2 (6)19 (7)0.842
Laboratory data
 Creatinine, mg/dl0.9 (0.8−1.2)1.1 (0.7−1.3)0.9 (0.8−1.1)0.425
 White blood cell count, K/μl5.8 (4.2−7.0)6.7 (5.7−8.6)5.6 (4.1−6.9)0.005
 Lymphocyte count, K/μl0.9 (0.7−1.2)0.8 (0.6−1.3)0.9 (0.7−1.2)0.812
 Hemoglobin, g/dl13.0 (12.0−14.5)12.5 (11.2−14.1)13.1 (12−14.5)0.521
 Platelet count, K/μl197 (158−245)173 (157−256)197 (163−246)0.644
 Aspartate aminotransferase, IU/l31 (23−52)29 (22−74)31 (24−52)0.131
 Alanine aminotransferase, IU/l21 (13−38)21 (13−44)20 (13−35)0.769
 Total bilirubin, mg/dl0.5 (0.4−0.8)0.7 (0.4−0.9)0.5 (0.4−0.8)0.718
 Albumin, mg/dl3.6 (3.3−3.8)3.5 (3.3−3.7)3.6 (3.3−3.8)0.157
 High-sensitivity troponin, ng/l10 (5−21)21 (12−37)9 (4−21)0.935
 Cardiac injury117 (37)21 (62)96 (34)0.002
 Brain natriuretic peptide, pg/ml36 (18−79)77 (36−183)32 (16−71)0.758
 Elevated brain natriuretic peptide94 (39)16 (57)78 (37)0.040
 Lactate dehydrogenase, IU/l319 (257−415)328 (269−450)316 (252−395)0.157
 Ferritin, ng/ml331 (159−810)409 (237−875)329 (155−837)0.685
 D-dimer, μg/ml0.89 (0.49−1.46)1.12 (0.48−2.815)0.78 (0.49−1.37)0.009
ECG characteristics
 Sinus rhythm273 (87)32 (94)241 (86)0.189
 Sinus tachycardia100 (32)12 (35)88 (31)0.648
 Atrial fibrillation/flutter9 (3)0 (0)9 (3)0.289
 Heart rate103 (91−111.75)101 (90−107)103 (91−112)0.677
 QRS duration84 (78−97.5)118 (80−145)84 (78−92)0.044
 QTc duration438 (421−461)449 (429−493)435 (420−457)<0.001
 Any injury pattern33 (11)4 (12)29 (10)0.800
 Prolonged QTc82 (26)18 (53)64 (23)<0.001
 First-degree AV block11 (4)1 (3)10 (4)0.936
Chest imaging findings
 Normal47 (15)2 (6)45 (16)0.099
 Unilateral pneumonia44 (14)4 (12)40 (14)
 Bilateral pneumonia94 (30)16 (47)78 (28)
 Multifocal pneumonia129 (41)12 (35)117 (42)

Values are mean ± SD, n (%), and median (interquartile range).

AV = atrioventricular; ECG = electrocardiography; RHS-ECG = new right heart strain patterns on presenting 12-lead electrocardiogram; SPO2/FiO2 = ratio of peripheral capillary oxygen saturation to the fraction of inspired oxygen.

Cardiac injury as defined by a troponin level above the 99th percentile (18 ng/l).

Elevated brain natriuretic peptide as defined by a level >50 pg/l.

Clinical Characteristics of Patients According to the Presence or Absence of Signs of RHS on the Presenting 12-Lead ECG Values are mean ± SD, n (%), and median (interquartile range). AV = atrioventricular; ECG = electrocardiography; RHS-ECG = new right heart strain patterns on presenting 12-lead electrocardiogram; SPO2/FiO2 = ratio of peripheral capillary oxygen saturation to the fraction of inspired oxygen. Cardiac injury as defined by a troponin level above the 99th percentile (18 ng/l). Elevated brain natriuretic peptide as defined by a level >50 pg/l. ECGs from the ED were read by G.S. and S.P., who were blinded to data and outcomes. ECG signs suggestive of RHS were defined by any of the following: new right-axis deviation, S1Q3T3 pattern; or ST-segment depressions with T-wave inversions in leads V1 to V3 and leads II, III, aVF not present on a previous ECG. Cardiac injury on 12-lead ECG was defined by any ST-segment elevation, depression, or T-wave flattening or inversion that was not due to repolarization abnormalities. Cardiac injury via laboratory data was defined by a high-sensitivity troponin level >99th percentile (4,5) (>18 ng/l in our assay). The degree of hypoxia was measured as the ratio of peripheral capillary oxygen saturation (SpO2) to the fraction of inspired oxygen (FiO2) (SPO2:FiO2), in accordance with the original mSOFA (Modified Sequential Organ Failure Assessment) investigations (6). SpO2 values were obtained from pulse oximetry ED vital logs or arterial blood gases. For those who were not intubated, FiO2 was estimated by multiplying liter flow per minute by 0.03 and adding that to 0.21, in accordance with original mSOFA investigations (6). The primary outcomes were mortality, need for mechanical ventilation, and their composite. The secondary outcomes were acute kidney injury (AKI), need for renal replacement therapy, acute respiratory distress syndrome (ARDS), and different composites of the mentioned outcomes. ARDS was defined according to the Berlin definition (7), and AKI was defined according to the Kidney Disease: Improving Global Outcomes criteria for creatinine (8). The cohort was categorized based on the presence of RHS-ECG (Table 1) and the primary outcomes (Supplemental Table 1).

Statistical analysis

The clinical data elements of different groups were compared using the chi-square test for categorical variables and analysis of variance or Kruskal-Wallis test for continuous variables based on the normality of the data. Univariate analysis was first done to identify the significant variables associated with the designed primary outcome. Multivariable logistic regression analysis was then performed to identify significant predictors of that outcome. Candidate variables for model inclusion included statistically and clinically relevant variables associated with COVID-19 critical illness (9,10) and those with a p value ≤0.05 on univariable analysis for our primary outcomes. The model exit criteria was p ≥0.1. This study was approved by the Institutional Review Board (#13774), and informed consent was waived.

Results

ECGs from the ED were available for 314 of 480 patients and were included in the analysis. Almost all patients were in sinus rhythm, with sinus tachycardia being the most frequent dysrhythmia. The mean age was 60 ± 14 years, and 151 (48%) were women. There were 34 (11%) patients with new RHS-ECGs that were not present on previous ECGs.

Baseline clinical and laboratory characteristics of patients with COVID-19 according to presence of ECG signs of RHS

There were several differences between patients with RHS-ECGs and those without. Patients with RHS-ECGs were older and statistically more likely to have a history of cerebrovascular disease, chronic obstructive pulmonary disease, and be smokers (all p < 0.05). These patients were also more likely to have risk factors for cardiovascular disease (diabetes mellitus, coronary artery disease, chronic kidney disease); however, the difference did not reach statistical significance (Table 1). Baseline laboratory data, including inflammatory markers, were compared between both groups. Upon admission, patients with RHS-ECGs had higher D-dimer levels (1.12 μg/ml vs. 0.78 μg/ml; p = 0.009), but there were no differences in baseline lactate dehydrogenase and ferritin levels (Table 1). Patients with RHS-ECGs were more likely to have elevated brain natriuretic peptide levels in addition to cardiac injury as defined by a troponin level >99th percentile. There was no statistical difference in chest imaging findings (Table 1). Among the 40 patients who had new ECG patterns suggestive of RHS, there were 17 (54%) with new right-axis deviation, 13 (38%) with S1Q3T3 patterns, and 11 (32%) with ST-segment depressions with T-wave inversions in leads V1 to V3 or leads II, III, and aVF that were not present on previous ECGs. In addition, 10 (29%) patients had an early R/S transition within the anterior chest leads. Table 2 lists the different combinations observed.
Table 2

Patterns of 12-Lead ECG Findings Consistent With RHS-ECG

RAD6
S1Q3T34
RBBB + RAD4
STD and TWI V1 to V4 or II-III-aVF3
RAD + early R/S transition3
RBBB + STD and TWI V1 to V4 or II-III-aVF3
RBBB + S1Q3T32
STD and TWI V1 to V4 or II-III-aVF2 + early R/S transition2
RAD + S1Q3T32
S1Q3T3 + early R/S transition1
RBBB + S1Q3T3 + STD & TWI V1 to V4 or II-III-aVF + early R/S transition1
Incomplete RBBB + S1Q3T3 + STD and TWI V1 to V4 or II-III-aVF + early R/S transition1
RAD + S1Q3T3 + early R/S transition1
RAD + S1Q3T3 + STD & TWI V1 to V4 or II-III-aVF + early R/S transition1

Values are n.

RAD = right-axis deviation; RBBB = right bundle branch block; STD = ST-segment depressions; TWI = T-wave inversion; other abbreviations as in Table 1

Patterns of 12-Lead ECG Findings Consistent With RHS-ECG Values are n. RAD = right-axis deviation; RBBB = right bundle branch block; STD = ST-segment depressions; TWI = T-wave inversion; other abbreviations as in Table 1 Only 2 of 40 patients had computed tomography angiograms performed to rule out pulmonary embolism, and one-half of the tests were positive. An echocardiogram was performed on 4 of 40 patients, and RV dysfunction was present in 3 of 4 patients (sample ECG and echocardiogram of a sample patient are shown in Supplemental Figure 1 and Videos 1A and 1B, respectively).

Baseline clinical and laboratory characteristics of patients with COVID-19 according to the primary outcomes

Mortality and the need for mechanical ventilation in the COVID-19 cohort were 15% and 18%, respectively. The characteristics of the overall population, according to the primary outcomes, are listed in Supplemental Table 1. Patients who were intubated were more likely to be men, and those who were deceased were more likely to be older (Supplemental Table 1). Patients who were intubated or died had a lower SPO2/FiO2 ratio in the ED (Supplemental Table 1) and were more likely to have ECG findings suggestive of RHS (Supplemental Table 1). Patients who required mechanical ventilation were more likely to have atrial fibrillation on ECG. Patients who were intubated or died were more likely to have a higher number of comorbidities, including heart failure, atrial fibrillation, cerebrovascular disease, chronic kidney disease, chronic obstructive pulmonary disease, and be smokers (Supplemental Table 1). They were also more likely to have higher high-sensitivity troponin lactate dehydrogenase, ferritin, and D-dimer levels. There was also no difference in chest imaging findings between the different outcome groups (Supplemental Table 1).

Outcomes according to the presence of signs of RHS on ECG

Patients with RHS-ECGs were significantly more likely to be intubated, discharged deceased, or their composite, as outlined in the multivariable analysis section in the following (Figure 1 , Table 3 , Central Illustration , and Supplemental Table 2). Furthermore, these patients were more likely to develop AKI and ARDS, as well as require renal replacement therapy (Figure 1 and Supplemental Table 2). There was no statistical difference in the median time to intubation (2 days; interquartile range [IQR]: 0 to 4 days vs. 2 days; IQR: 0 to 3 days; p = 0.199) or mortality (9 days; IQR: 5 to 13 days and 13 days; IQR: 7 to 15.5 days; p = 0.26). The statistical performance of RHS-ECG in relation to our primary outcomes were as follows: mechanical ventilation (sensitivity: 50%; 95% confidence interval [CI]: 32% to 68%; specificity: 94%; 95% CI: 90% to 96%); mortality (sensitivity: 40%; 95% CI: 26% to 56%; specificity: 94%; 95% CI: 91% to 97%); and composite of mortality or mechanical ventilation (sensitivity: 31%; 95% CI: 20% to 44%; specificity: 90%; 95% CI: 91% to 97%). The presence of RHS-ECG also provides an early and powerful discriminatory ability for the risk of mechanical ventilation (Figure 2A ), mortality (Figure 2B), and their composite (Central Illustration).
Figure 1

Incidence of Different Outcomes According to the Presence of RHS Patterns on Presenting 12-Lead ECG

Outcomes of patients according to right heart strain−electrocardiograms (RHS-ECGs). Patients with RHS-ECGs had a higher incidence of all primary and secondary outcomes (all p < 0.05). CI = confidence interval; ICU = intensive care unit: Mech Vent = mechanical ventilation.

Table 3

Predictors of Inpatient Mortality, Need for Mechanical Ventilation, and Their Composite After Multivariable Regression Using Clinical Data Elements From the Emergency Department

Unadjusted OR (95% CI); p ValueAdjusted OR (95% CI); p Value
Mortality
 RHS-ECG11.4 (5.2−24.9); <0.00115.2 (5.1−45.2); <0.001
 SPO2/FiO20.80 (0.74−0.86); <0.0010.81 (0.74−0.89); <0.001
 Cerebrovascular disease7.7 (2.5−24.3); <0.0019.0 (1.6−50.7); 0.013
 Cardiac injury6.6 (3.3−13.3); <0.0013.8 (1.5−9.6); 0.004
 Ferritin1.3 (1.1−1.7); 0.0141.4. (1.1−1.9); 0.031
 Smoking history3.5 (1.9−6.8); <0.0013.1 (1.2−7.7); 0.016
Mechanical ventilation
 RHS-ECG6.4 (3.0−13.5); <0.0018.8 (3.4−23.2); <0.001
 Cerebrovascular disease6.2 (2.0−19.4); <0.0015.5 (1.3−21.7); <0.016
 SPO2/FiO20.78 (0.72−0.84); <0.0010.80 (0.74−0.87); <0.001
 Lactate dehydrogenase1.3 (1.2−1.5); <0.0011.2 (1.1−1.4); 0.013
Composite of mortality or mechanical ventilation
 RHS-ECG7.7 (3.6−16.3); <0.00112.1 (4.3−33.9); <0.001
 Cerebrovascular disease7.0 (2.2−22.4); <0.0017.8 (1.8−33.9); 0.006.
 SPO2/FiO20.76 (0.71−0.82); <0.0010.77 (0.70−0.84); <0.001
 Lactate dehydrogenase1.3 (1.1−1.5); <0.0011.2 (1.1−1.3); 0.037

Variables controlled for RHS-ECG, age 65 yrs or older, cardiac injury, atrial fibrillation/ flutter, cerebrovascular disease, chronic kidney disease, chronic obstructive lung disease, smoking history, SPO2/FiO2, lactate dehydrogenase, ∗ferritin, and ∗D-dimer.

CI = confidence interval; OR = odds ratio; other abbreviations as in Table 1.

Continuous variables were converted to a 20-point scale with their maximal laboratory value (per assay) corresponding to 20 points.

Central Illustration

Incidence and Survival Curves of Primary Outcomes According to the Presence of Right Heart Strain Patterns on Presenting 12-Lead Electrocardiogram

Patients with right heart strain−electrocardiograms (RHS-ECGs) on presentation to the emergency department had a significantly higher incidence of in-patient need for mechanical ventilation (Mech Vent) and/or mortality. The Kaplan-Meier curves illustrate the powerful and early discriminatory ability of the presence of RHS-ECGs for the risk of the composite of mortality and the need for Mech Vent. CI = confidence interval.

Figure 2

Intubation and Mortality Kaplan-Meier Survival-Curves for Patients According to the Presence of RHS Patterns on 12-Lead ECG

Comparison of (A) Mech Vent and (B) mortality rates among patients with and without RHS-ECG as obtained in the emergency department. The Kaplan-Meier curves illustrate the powerful and early discriminatory ability of the presence of RHS-ECGs on the risk of (A) Mech Vent and (B) mortality. Abbreviations as in Figure 1.

Incidence of Different Outcomes According to the Presence of RHS Patterns on Presenting 12-Lead ECG Outcomes of patients according to right heart strain−electrocardiograms (RHS-ECGs). Patients with RHS-ECGs had a higher incidence of all primary and secondary outcomes (all p < 0.05). CI = confidence interval; ICU = intensive care unit: Mech Vent = mechanical ventilation. Predictors of Inpatient Mortality, Need for Mechanical Ventilation, and Their Composite After Multivariable Regression Using Clinical Data Elements From the Emergency Department Variables controlled for RHS-ECG, age 65 yrs or older, cardiac injury, atrial fibrillation/ flutter, cerebrovascular disease, chronic kidney disease, chronic obstructive lung disease, smoking history, SPO2/FiO2, lactate dehydrogenase, ∗ferritin, and ∗D-dimer. CI = confidence interval; OR = odds ratio; other abbreviations as in Table 1. Continuous variables were converted to a 20-point scale with their maximal laboratory value (per assay) corresponding to 20 points. Incidence and Survival Curves of Primary Outcomes According to the Presence of Right Heart Strain Patterns on Presenting 12-Lead Electrocardiogram Patients with right heart strain−electrocardiograms (RHS-ECGs) on presentation to the emergency department had a significantly higher incidence of in-patient need for mechanical ventilation (Mech Vent) and/or mortality. The Kaplan-Meier curves illustrate the powerful and early discriminatory ability of the presence of RHS-ECGs for the risk of the composite of mortality and the need for Mech Vent. CI = confidence interval. Intubation and Mortality Kaplan-Meier Survival-Curves for Patients According to the Presence of RHS Patterns on 12-Lead ECG Comparison of (A) Mech Vent and (B) mortality rates among patients with and without RHS-ECG as obtained in the emergency department. The Kaplan-Meier curves illustrate the powerful and early discriminatory ability of the presence of RHS-ECGs on the risk of (A) Mech Vent and (B) mortality. Abbreviations as in Figure 1.

Multivariable analysis for the independent predictors of inpatient need for mechanical ventilation and mortality

A multivariable regression analysis for intubation and for mortality used clinical variables that were independently associated with each outcome (Table 2). Age 65 years or older was used, and cardiac injury was defined as a high-sensitivity troponin level >99th percentile (>18 ng/l, per our assay) (5). Continuous variables were converted to a 20-point scale based on the highest value that our assay would measure (ferritin, D-dimer, and lactate dehydrogenase) and on the highest ratio obtainable on room air (SPO2 = 100% and FiO2 = 0.21) for SPO2/FiO2. RHS-ECG continued to be independently associated with mortality (adjusted odds ratio [adjOR]: 15.2; 95% CI: 5.1 to 45.2; p < 0.001) (Table 3), the need for mechanical ventilation (adjOR: 8.8; 95% CI: 3.4 to 23.2; p < 0.001) (Table 3), and their composite (adjOR: 12.1; 95% CI: 4.3 to 33.9; p < 0.001) (Table 3).

Discussion

In this study, we described the characteristics and outcomes of patients hospitalized with COVID-19 according to RHS-ECGs on the presenting ECG obtained in the ED. This study revealed that RHS-ECGs were associated with a higher risk of worse outcomes, including mortality, mechanical ventilation, AKI, renal replacement therapy, and ARDS. Cardiovascular comorbidities were shown to be associated with a higher risk of morbidity and mortality in patients admitted with COVID-19 (11,12). Several studies also revealed that cardiac injury, as evidenced by elevated troponin, is associated with worse outcomes, including ARDS and mortality (4). The link between the mechanism of cardiac injury associated with COVID-19 and worse outcomes is not well elucidated. In our study, we observed an association between RHS-ECGs and cardiac injury, both of which were independent predictors of worse outcomes in patients admitted with COVID-19. It is difficult to assess direct causation, especially because these ECG signs suggested RV strain and were mostly not supported by further evaluation. However, a few speculations could be drawn. In our study, 3 of 4 of echocardiograms performed on patients with RHS-ECGs revealed findings consistent with RV dysfunction. Published studies and case series showed that RV dysfunction appears to be the predominant cardiac pathology on the in-patient echocardiograms performed (13). The mechanism of RV dysfunction could be due to multiple factors. Respiratory failure is the most common cause of death in patients admitted with COVID-19. Hypoxic vasoconstriction or physical destruction of the capillary beds that leads to elevated pulmonary vascular resistance is one of the proposed mechanisms of RV dysfunction. RHS-ECGs continued to be an independent predictor of the need for mechanical ventilation or mortality, even after factoring in the degree of hypoxia using the SPO2:FiO2 ratios. Patients admitted with COVID-19 also had an increased prevalence of venous thromboembolism (14, 15, 16), and autopsies revealed a marked presence of pulmonary microthrombosis (17), which could result in RV strain. Unfortunately, acute pulmonary emboli were not well accounted for, because there were only 2 patients who had a dedicated computed tomographic pulmonary angiography. Adding D-dimer to the multivariable analysis did not null the effect of the association of RHS-ECGs with mortality or the need for mechanical ventilation. Respiratory and cardiac complications are life-threatening diagnostic dilemmas in patients with COVID-19 (2,18). Patients with evidence of RHS on initial ECGs had significantly higher rates of mechanical ventilation and mortality, which was not previously reported. Do et al. (19) demonstrated that continuous ECG changes on telemetry consistent with RHS preceded asystole and/or pulseless electrical activity arrest from hypoxic respiratory failure. It was also possible that patients with RHS-ECGs in our cohort represented those who presented later in the course of their COVID-19 illness. This was also further evidence that RV dysfunction was an end-stage complication before adverse events. Among available clinical tools, ECGs are easily performed, cost-effective, and widely available. The detection of RHS-ECGs provided a simple and powerful tool with early discriminatory ability, as early as presentation to the ED. However, only 314 of 480 (65%) patients in our cohort had an ECG obtained in the ED, with even lower rates in a previous published cohort from Wuhan (4). We suggest obtaining a baseline ECG for all patients admitted with COVID-19 because identification of RHS-ECG may guide early triage and management of these patients.

Study limitations and future directions

The main limitation of our study was its retrospective design. Despite controlling for multiple variables, there might be confounding variables for which we did not account. The patient population chosen included those who were admitted, and they could not be generalized to all patients with COVID-19. Furthermore, patients were excluded if they were still admitted at the time of data collection and analysis because our primary outcome could not be accurately assessed. Although ECG findings suggestive of RHS conferred worse outcomes, the data available did not allow correlation with echocardiographic findings, nor did they allow a complete assessment of possible etiologies (e.g., pulmonary emboli). Larger prospective studies will be required to validate and better characterize our results in relationship to echocardiographic evidence of RV strain in addition to potential mechanisms such as pulmonary embolism. The temporality of RHS-ECG patterns could not be ascertained entirely despite being new compared with previous ECGs present. Therefore, these findings might have been present before admission and not related to COVID-19. However, these findings were still beneficial for risk prediction because our results revealed an early discriminatory ability of RHS-ECGs when obtained as early as presentation to the ED. Prospective trials will help address this limitation in addition to any benefit in serial risk prediction with serial in-patient ECG or telemetry monitoring to assess whether the evolution and/or resolution of RHS-ECGs confers different inpatient risks.

Conclusions

The presence of RHS-ECGs was associated with an increased risk of critical illness in patients admitted with COVID-19. Special attention should be given to patients with COVID-19 with RHS-ECGs. COMPETENCY IN MEDICAL KNOWLEDGE: SARS-CoV-2 is a highly contagious and virulent pathogen. In areas of high case density where resource allocation is desperately needed, cost-effective and easily performed tests that can risk stratify patients are invaluable. In our study, the detection of new RHS patterns on the presenting ECG predicted critical illness in patients admitted with COVID-19. This could potentially facilitate early triage and management of patients with COVID-19 presenting to the ED with RV strain. In addition, this finding highlighted the role of RV dysfunction in the pathophysiology of COVID-19. TRANSLATIONAL OUTLOOK: Validation of our findings in a larger prospective patient population will provide a novel prognostic marker that can be used in prediction models to facilitate appropriate patient triage and resource allocation.

Funding Support and Author Disclosures

The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
  2 in total

1.  Electrocardiogram-based mortality prediction in patients with COVID-19 using machine learning.

Authors:  R R van de Leur; H Bleijendaal; K Taha; T Mast; J M I H Gho; M Linschoten; B van Rees; M T H M Henkens; S Heymans; N Sturkenboom; R A Tio; J A Offerhaus; W L Bor; M Maarse; H E Haerkens-Arends; M Z H Kolk; A C J van der Lingen; J J Selder; E E Wierda; P F M M van Bergen; M M Winter; A H Zwinderman; P A Doevendans; P van der Harst; Y M Pinto; F W Asselbergs; R van Es; F V Y Tjong
Journal:  Neth Heart J       Date:  2022-03-17       Impact factor: 2.854

2.  Prognostic Value of 12-Leads Electrocardiogram at Emergency Department in Hospitalized Patients with Coronavirus Disease-19.

Authors:  Giulia Savelloni; Maria Chiara Gatto; Francesca Cancelli; Anna Barbetti; Francesco Cogliati Dezza; Cristiana Franchi; Martina Carnevalini; Gioacchino Galardo; Tommaso Bucci; Maria Alessandroni; Francesco Pugliese; Claudio Maria Mastroianni; Alessandra Oliva
Journal:  J Clin Med       Date:  2022-04-30       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.